CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 68 enrolled
Drug / intervention
Nicotinamide (NAM) +3 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05517122
NCT05517122N/ACompleted
CompareCT.gov

Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults

Société des Produits Nestlé (SPN)·interventional·Posted Aug 26, 2022·Updated Apr 24, 2025

In Brief

A clinical study evaluating Nicotinamide (NAM), Nicotinamide Riboside (NR), and 2 other interventions for Healthy. Completed, enrolled 68 participants across 1 site.

Detailed Summary

Nicotinamide adenine dinucleotide (NAD) is a coenzyme playing a central role in human metabolic pathways. A recognized approach to increase NAD level is through oral supplementation of its precursors promoting NAD synthesis in vivo. NAD precursors exist in multiple forms. However, it is unclear how the various precursors compare in their ability to increase NAD levels in human blood. The purpose of this study is to compare the effect of 3 NAD precursors on whole blood NAD metabolome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSwitzerland
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedAug 26, 2022
Enrollment StartJul 12, 2022
Primary CompletionNov 24, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.9 years ago

Interventions

Nicotinamide (NAM)dietary

500 mg a day

Nicotinamide Riboside (NR)dietary

1000 mg a day

Nicotinamide Mono Nucleotide (NMN)dietary

1000 mg a day

Microcrystalline cellulosedietary

500 mg a day